Compare Shell PLC (SHEL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Smith & Nephew plc — how do they compare? Shell PLC trades at $95.99 (market cap $271.34B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Shell PLC is far larger — about 23.3× Smith & Nephew plc's market cap, and Shell PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals.
| SHEL | SNN | |
|---|---|---|
Market Cap | $271.34B | $11.63B |
Sector | Energy | Health |
52-Week High | $95.60 | $38.53 |
52-Week Low | $70.31 | $27.80 |
Enterprise Value | $313.04B | $14.66B |
Dividend Yield | 3.28% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $95.32, up 2.55% on the day and near its record high, driven by strong crude oil prices and positive earnings momentum with recent quarterly beats. The stock shows a bullish technical outlook, supported by moving averages, while fundamentals reflect solid profitability with an 8.76% net margin and attractive valuation metrics like a P/E of 10.54. Recent developments include strategic acquisitions in deepwater projects and retail expansion, enhancing growth prospects.
The outlook for SHEL remains positive, with analyst consensus favoring a buy rating and a $101 price target, implying upside potential. Key opportunities include oil price tailwinds and operational efficiency, though risks involve revenue volatility from energy markets and geopolitical tensions, as highlighted by recent news. Investors should weigh robust cash flows against cyclical industry headwinds.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
